Description

5H-Pyrido[2,3-B][1,5]Benzodiazepine,6,11-Dihydro-11-Methyl-(9Ci) is a high-purity, advanced pharmaceutical intermediate belonging to the benzodiazepine class of heterocyclic compounds. This compound is of significant value for research and development in medicinal chemistry, particularly for its potential role as a key building block in the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily needed by pharmaceutical R&D laboratories, contract research organizations (CROs), and fine chemical manufacturers focused on developing new therapeutic agents targeting the central nervous system and other disease areas.

Application

• Pharmaceutical Intermediate: Serves as a critical precursor in the multi-step synthesis of novel benzodiazepine-based drug candidates.
• Medicinal Chemistry Research: Used as a scaffold or building block for structure-activity relationship (SAR) studies to optimize biological activity and pharmacokinetic properties.
• Reference Standard: Employed as an analytical standard in method development and quality control for related pharmaceutical compounds.
• Chemical Biology Probes: Utilized in the development of molecular probes to study biological pathways and receptor interactions.
• Academic Research: Applied in university and institutional labs for fundamental studies in organic synthesis and heterocyclic chemistry.
• Process Development: Used in the scale-up and optimization of synthetic routes for potential commercial drug manufacturing.

Basic Information

Product Name	5H-Pyrido[2,3-B][1,5]Benzodiazepine,6,11-Dihydro-11-Methyl-(9Ci)
CAS No.	805247-91-0
Molecular Formula	C13H13N3
Molecular Weight	211.26 g/mol
Synonyms	6,11-Dihydro-11-methyl-5H-pyrido[2,3-b][1,5]benzodiazepine; 11-Methyl-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine; 5H-Pyrido[2,3-b][1,5]benzodiazepine, 6,11-dihydro-11-methyl-; 11-Methyl-5H-pyrido[2,3-b][1,5]benzodiazepin-6(11H)-one (tautomer); Pyrido-benzodiazepine derivative; 805247-91-0; 11-Methyl-dihydro-pyrido-benzodiazepine
EINECS	Contact for details

Quality Control

Our 5H-Pyrido[2,3-B][1,5]Benzodiazepine,6,11-Dihydro-11-Methyl-(9Ci) is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and consistency. We provide comprehensive Certificates of Analysis (COA) with each shipment, detailing results from HPLC, NMR, and mass spectrometry. Our quality commitment aligns with cGMP principles for pharmaceutical intermediates, ensuring reliability for your critical R&D and scale-up processes.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (typically 15-25°C). The compound should be kept under an inert atmosphere if long-term storage is required to prevent potential degradation. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	Off-white to light yellow powder
Identification (HPLC)	Conforms
Identification (NMR)	Conforms
Purity (HPLC)	≥ 97.0%
Related Substances (HPLC)	Total impurities ≤ 3.0%
Residual Solvents (GC)	Meets ICH guidelines
Water Content (KF)	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.